Virchows Archiv

, Volume 458, Issue 5, pp 615–620 | Cite as

MUC1 expression in thymic epithelial tumors: MUC1 may be useful marker as differential diagnosis between type B3 thymoma and thymic carcinoma

  • Kyoichi Kaira
  • Haruyasu Murakami
  • Masakuni Serizawa
  • Yasuhiro Koh
  • Masato Abe
  • Yasuhisa Ohde
  • Toshiaki Takahashi
  • Haruhiko Kondo
  • Takashi Nakajima
  • Nobuyuki Yamamoto
Original Article

Abstract

MUC1 is a transmembrane mucin that has been related to tumor progression and outcome in various malignancies. However, the clinical significance in thymic epithelial tumors remains unknown. We investigated the clinical significance of MUC1 expression in thymic epithelial tumors. Fifty-five patients with thymic epithelial tumors were included in this study. Tumors sections were stained by immunohistochemistry for MUC1, vascular endothelial growth factor (VEGF), microvessel density (MVD) determined by CD34, and p53. MUC1 were expressed in 29%. The expression of MUC1 was significantly correlated with the grade of malignancy in thymic epithelial tumors. MUC1 was closely associated with VEGF, p53 and MVD, and the overexpression of MUC1 was a prognostic marker for predicting poor outcome in univariate analysis. A positive rate of MUC1 expression was 94% (16/17) in thymic carcinomas and 0% (0/5) in type B3 thymomas, demonstrating a significant difference (p < 0.0001). The expression of MUC1 was closely related to the grade of malignancy in thymic epithelial tumors. A positive expression of MUC1 was significantly associated with poor outcome in this disease. MUC1 may be useful marker for differentiating thymic carcinoma from type B3 thymoma.

Keywords

MUC1 Thymic epithelial tumor Prognosis Thymic carcinoma Type B3 thymoma 

Notes

Acknowledgments

This work was supported in part by Grant 21790793 (K. K) from the Ministry of Education, Culture, Sports, Science, and Technology, Japan, and National Hospital Organization Policy Based Medical Services.

We thank all the staff of the Department of Pathology in Shizuoka Cancer Center for their technical assistance of immunohistochemical analysis.

Conflicts of interest statement

We, all authors, have no financial or personal relationships with other people or organizations that could inappropriately influence our work.

References

  1. 1.
    Engels EA, Pfeiffer RW (2003) Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer 105:546–551PubMedCrossRefGoogle Scholar
  2. 2.
    Rosai J, Sobin LH (1999) Histological typing of tumours of the thymus, International histological classification of tumours, 2nd edn. Springer, New York, pp 1–59Google Scholar
  3. 3.
    Travis WD, Brambillia E, Muller-Hermelink HK (2004) WHO classification of tumors. Pathology and genetics of tumors of the lung, pleura, thymus and heart. IARC Press, LyonGoogle Scholar
  4. 4.
    Gendler SJ, Lancaster CA, Taylor-Papadimitriou J et al (1990) Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 265:15286–15293PubMedGoogle Scholar
  5. 5.
    Schroeder JA, Masril AA, Adriance MC et al (2004) MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene 23:5739–5747PubMedCrossRefGoogle Scholar
  6. 6.
    Nagai S, Takenaka K, Sonobe M et al (2006) A novel classification of MUC1 expression is correlated with tumor differentiation and postoperative prognosis in non-small cell lung cancer. J Thorac Oncol 1:46–51PubMedCrossRefGoogle Scholar
  7. 7.
    Broadbent R, Thynne G, McKenzie IFC (1997) Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J Clin Invest 100:2783–2792PubMedCrossRefGoogle Scholar
  8. 8.
    Woenckhaus M, Merk J, Stoehr R et al (2008) Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer. Hum Pathol 39:126–136PubMedCrossRefGoogle Scholar
  9. 9.
    Masaoka A, Monden Y, Nakahara K et al (1981) Follow-up study of thymomas with special reference to their clinical stages. Cancer 48:2485–2492PubMedCrossRefGoogle Scholar
  10. 10.
    Kaira K, Endo M, Abe M et al (2010) Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol 28:3746–3753PubMedCrossRefGoogle Scholar
  11. 11.
    Utsunomiya T, Yonezawa S, Sakamoto H et al (1998) Expression of MUC1 and MUC2 mucins in gastric carcinomas: its relationship with the prognosis of the patients. Clin Cancer Res 4:2605–2614PubMedGoogle Scholar
  12. 12.
    Hinoda Y, Ikematsu Y, Horinouchi M et al (2003) Increased expression of MUC1 in advanced pancreatic cancer. J Gastroenterol 38:1162–1166PubMedCrossRefGoogle Scholar
  13. 13.
    Tamada S, Goto M, Nomoto M et al (2002) Expression of MUC1 and MUC2 mucins in extrahepatic bile duct carcinomas: its relationship with tumor progression and prognosis. Pathol Int 52:713–723PubMedCrossRefGoogle Scholar
  14. 14.
    Kawamoto T, Shoda J, Miyahara N et al (2004) Expression of MUC1 recognized by a monoclonal antibody MY.1E12 is a useful biomarker for tumor aggressiveness of carcinoma of the gallbladder. Clin Exp Metastasis 21:353–362PubMedCrossRefGoogle Scholar
  15. 15.
    Feng H, Ghazizadeh M, Konishi H et al (2002) Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas. Jpn J Clin Oncol 32:525–529PubMedCrossRefGoogle Scholar
  16. 16.
    Sivridis E, Giatromanolaki A, Koukourakis MI et al (2002) Patterns of episialin/MUC1 expression in endometrial carcinomas and prognostic relevance. Histopathology 40:92–100PubMedCrossRefGoogle Scholar
  17. 17.
    Baldus SE, Monig SP, Huxel S et al (2004) MUC1 and nuclear beta-catenin are coexpressed at the invasion front of colorectal carcinomas and are both correlated with tumor prognosis. Clin Cancer Res 10:2790–2796PubMedCrossRefGoogle Scholar
  18. 18.
    Kirschenbaum A, Itzkowitz SH, Wang JP et al (1999) MUC1 expression in prostate carcinoma: correlation with grade and stage. Mol Urol 3:163–168PubMedGoogle Scholar
  19. 19.
    Kojika M, Ishii G, Yoshida J et al (2010) Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma: diagnostic utility of hypoxic marker, GLUT1, in thymic epithelial neoplasms. Modern Pathol 22:1341–1350CrossRefGoogle Scholar
  20. 20.
    Kontani K, Taguchi O, Ozaki Y et al (2003) Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucins. Int J Mol Med 12:493–502PubMedGoogle Scholar
  21. 21.
    Kufe DW (2009) Functional targeting of the MUC1 oncogene in human cancers. Cancer Biol Ther 8:1197–1203PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Kyoichi Kaira
    • 1
  • Haruyasu Murakami
    • 1
  • Masakuni Serizawa
    • 1
    • 2
  • Yasuhiro Koh
    • 1
    • 2
  • Masato Abe
    • 1
    • 3
  • Yasuhisa Ohde
    • 1
    • 4
  • Toshiaki Takahashi
    • 1
  • Haruhiko Kondo
    • 1
    • 4
  • Takashi Nakajima
    • 1
    • 3
  • Nobuyuki Yamamoto
    • 1
  1. 1.Division of Thoracic OncologyShizuoka Cancer CenterShizuokaJapan
  2. 2.Division of Drug Discovery and DevelopmentShizuoka Cancer Center Research InstituteShizuokaJapan
  3. 3.Division of PathologyShizuoka Cancer CenterShizuokaJapan
  4. 4.Division of Thoracic SurgeryShizuoka Cancer CenterShizuokaJapan

Personalised recommendations